U.K.-based Epsilogen has bought Boston biotech TigaTx with the aim of creating “the world’s leading pan-isotype cancer antibody company.” Both companies are focused on immunoglobulin antibodies, with Epsilogen’s work orienting around IgE, while TigaTX has been hard at work developing IgA therapies. The deal, for which Epsilogen is not disclosing the financial details, will see TigaTx become a subsidiary of the London-based company. Source: Fierce Biotech 7/4/2025